Arvinas, Merck team up to create new therapeutics using protein degradation technology

Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.



from The Medical News http://ift.tt/1Jk2jn1